US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco S&P SmallCap Health Care ETF

51.63

+0.35410.69%

Post-market: 51.640.0069+0.01%19:30 EDT

Volume:8K

Turnover:410.51K

Market Cap:175.04M

PE:- -

High:51.99

Open:51.57

Low:51.54

Close:51.28

52wk High:56.45

52wk Low:39.08

Shares:3.39M

Float Shares:3.39M

Volume Ratio:0.38

T/O Rate:0.23%

Dividend:0.00

Dividend Rate:0.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell

MT Newswires Live

U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes

Alkermes jumps 8% to $46.99 after Phase I adult ADHD data

Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug

THOMSON REUTERS

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD

Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd

THOMSON REUTERS

Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)

THOMSON REUTERS

Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027

THOMSON REUTERS

Ultragenyx price target raised to $35 from $32 at Barclays

Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72

Alkermes Files Form 3 for Director Anne Clem Whitaker`

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE)

Corcept Says EU CHMP Backs Lifyorli Combo for Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated - Ec to Issue Final Approval Decision in Q4 2026

THOMSON REUTERS

Corcept Announces Chmp Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

THOMSON REUTERS

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

Ultragenyx confirms FDA approval of Fayuvi

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/PSCH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSCH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","market":"US","secType":"STK","nameCN":"Invesco S&P SmallCap Health Care ETF","latestPrice":51.6331,"timestamp":1790971200000,"preClose":51.279,"halted":0,"volume":7949,"hourTrading":{"tag":"盘后","latestPrice":51.64,"preClose":51.6331,"latestTime":"19:30 EDT","volume":9,"amount":464.6324,"timestamp":1790983802989,"change":0.0069,"changeRate":0.000134,"amplitude":0},"delay":0,"changeRate":0.006905360868971614,"floatShares":3390000,"shares":3390000,"eps":0,"marketStatus":"Market Closed","change":0.3541,"latestTime":"10-02 16:00:00 EDT","open":51.57,"high":51.99,"low":51.54,"amount":410508.641047,"amplitude":0.008776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":51.279,"sharesOutstanding":3220000,"nav":51.29067,"aum":175109072.55,"dividendRate":0.000058,"bidAskSpread":0.001911,"postHourTrading":{"tag":"盘后","latestPrice":51.64,"preClose":51.6331,"latestTime":"19:30 EDT","volume":9,"amount":464.6324,"timestamp":1790983802989,"change":0.0069,"changeRate":0.000134,"amplitude":0},"volumeRatio":0.3820202063487071,"impliedVol":0.1092,"impliedVolPercentile":0.7371},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","floatShares":3390000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3820202063487071,"shares":3390000,"dividePrice":0.003,"high":51.99,"amplitude":0.008776,"preClose":51.279,"low":51.54,"week52Low":39.08,"pbRate":"--","week52High":56.454,"institutionHeld":0,"latestPrice":51.6331,"eps":0,"divideRate":0.000058,"volume":7949,"delay":0,"ttmEps":0,"open":51.57,"prevYearClose":44.0553,"prevWeekClose":52.7945,"prevMonthClose":52.07,"prevQuarterClose":52.07,"fiveDayClose":52.7945,"twentyDayClose":54.7539,"sixtyDayClose":54.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSCH\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"PSCH","amount":0.00033,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-09-22","symbol":"PSCH","amount":0.00259,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PSCH","amount":0.00199,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-24","symbol":"PSCH","amount":0.01419,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSCH","amount":0.01801,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSCH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.01949,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00522,"currency":"USD"},{"executeDate":"2022-03-31","recordDate":null,"paymentDate":"2022-03-31","value":3,"currency":"USD"},{"executeDate":"2023-12-18","recordDate":"2023-12-19","paymentDate":"2023-12-22","value":0.00448,"currency":"USD"},{"executeDate":"2024-03-18","recordDate":"2024-03-19","paymentDate":"2024-03-22","value":0.03613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSCH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSCH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669316610","title":"InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316610","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316610?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:00","pubTimestamp":1789995600,"startTime":"0","endTime":"0","summary":"- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/21/3365503/0/en/inspiremd-announces-amendments-to-certain-series-j-and-series-k-warrants-providing-potential-gross-proceeds-of-up-to-11-million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","MRNY","LFSC","PSCH","IEIH","SYNB","MEDI","GNMX","RSPH","MRNX","PINK","NSPR","BMED","BK4585","BBP","BK4588","IBB","NVIB","TBXU","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669976165","title":"Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669976165","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669976165?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:43","pubTimestamp":1789994623,"startTime":"0","endTime":"0","summary":"Alkermes  said Monday its drug candidate ALKS 7290 showed clinically meaningful improvements from baseline on exploratory endpoints in a phase 1b study in patients with attention-deficit hyperactivity disorder or ADHD.The company said it measured improvements using the Adult ADHD Investigator Symptom Rating Scale and Clinical Global Impression-Severity Scale after 14 days of treatment.ALKS 7290 was generally well-tolerated at all doses tested in healthy volunteers and adults with ADHD, the company said. The study enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group trial with two cohorts, it added.The company said it enrolled the first of an expected 312 participants in a phase-2 study this month. The trial will evaluate the safety and efficacy of once-daily and split doses of ALKS 7290 compared to placebo, with data expected next year.Shares of the company were up over 7% in Monday's premarket activity.Price: 46.50, Change: +3.11, Percent Change: +7.17","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALKS","PSIL","IBRN","MEDX","BK4139","ABVC","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669099168","title":"U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2669099168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669099168?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:52","pubTimestamp":1789991524,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Accenture, Arhaus, AlkermesSeptember 21 (Reuters)-Wall Street futures advanced on Monday, led by AI stocks, as a 2% slide in oil prices pulled Treasury yields lower on sig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL6N45D0I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","PSIL","LU0942090050.USD","LU1894683264.USD","CONL","BK4547","LU2247934214.USD","COIX","BK4598","BK4566","HOOG","WNTR","SG9999014898.SGD","LU0738911758.USD","LU0289961442.SGD","IE00BSNM7G36.USD","LU0130102774.USD","HOOZ","HOYY","IE00BFSS8Q28.SGD","COIW","LU2133065610.SGD","LU0868494708.USD","BK4551","LU2381873111.SGD","BK4596","LU1861220207.SGD","BK4213","CONY","LU1116320901.HKD","MSTC","LU0661504455.SGD","LU1032466523.USD","COIA","07311","HOOY","HODU","MSDD","ROBN","SG9999018865.SGD","CUE","LU0265550946.USD","BK4535","LU1366333091.USD","MSTK","LU0157215616.USD","APED","MEDX","LU1989772923.USD","MSTZ","ALKS","LMI3.UK","LU1003077747.HKD","BULL","LU1585245621.USD","ICOI","FBT","LU0130517989.USD","CRMX","COIO","LU2360107671.USD","HOOD","BK4125","IBLC","LU0511384066.AUD","CRMU","BULU","3SMI.UK","BITQ","BK4581","LU1228905540.USD","MSTY.UK","BK4534","BK4585","MSTW","09399","IE00B7KXQ091.USD","LU0323239441.USD","MTYY","LU0342679015.USD","BK4600","COYY","GRML","LU1823568750.SGD","SG9999017495.SGD","LU2596442595.SGD","LU0265550359.USD","IE000M9KFDE8.USD","FIAT","BK4516","SGXZ23171101.USD","MSTP","BULG","HOOX","LU0477156953.USD","HOII","LU1861559042.SGD","LU2211815571.USD","MSII","HOOW","07799","HOOC","BPAY","PSCH","LU1201861249.SGD","07711","BK4112","BK4554","LU0175139822.USD","WBD","LU0980610538.SGD","CONX","MST","HK0000819398.USD","HOOI","LU0289960550.SGD","LU1861558580.USD","BK4134","BKCH","BK4178","09799","COIN","SG9999018857.SGD","LU0289739343.SGD","BLCK","SG9999014880.SGD","BK4588","LU0545562505.USD","IE0004445015.USD","LU1046421795.USD","PSKY","SG9999014914.USD","MSOO","MSST","LU1228905037.USD","FDIG","07399","SGXZ31699556.SGD","IE00BFSS7M15.SGD","SG9999014906.USD","BK4539","IAI","COII","LU1506573853.SGD","IE00BHPRN162.USD","LU1235294995.USD","LU0868494617.USD","IE00BJJMRY28.SGD","SMI3.UK","3LMI.UK","09711","GLND","MSTU","MSTY","BK4533","LU0648001328.SGD","SG9999004303.SGD","BK4561","IE00BJJMRX11.SGD","LU0949170772.SGD","LU0545039389.USD","ACN","MSTR","CONI","BK4595","LU1989772840.SGD","LU1116320737.USD","LU0149725797.USD","09311","BK4168","LU1430594728.SGD","COIG","BK4023","IMST","LU1861217088.USD","ARHS","LU0323240290.USD","OWNB","REXC","SMST","LU0553294199.USD","BK4108","BK4139","FINX","CRML","CRPT","LU1883839398.USD","MSTX","IBRN","BK4127","LU0081259029.USD","DAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163577","title":"Alkermes jumps 8% to $46.99 after Phase I adult ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163577?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:50","pubTimestamp":1789991414,"startTime":"0","endTime":"0","summary":"07:46 EDT Alkermes (ALKS) jumps 8% to $46.99 after Phase I adult ADHD data Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","PSCH","IBRN","FBT","ALKS","MEDX","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150485","title":"Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150485?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:07","pubTimestamp":1789988867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSCH","FBT","PSIL","MEDX","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916887","title":"Alkermes announces Phase 1b results of ALKS 7290 in ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916887?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:05","pubTimestamp":1789988737,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) announced topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","ABVC","PSCH","BK4139","PSIL","FBT","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669415062","title":"Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669415062","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669415062?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:01","pubTimestamp":1789988517,"startTime":"0","endTime":"0","summary":"Alkermes reports positive Phase 1b proof-of-concept data for ALKS 7290 in adult ADHDAlkermes reported positive Phase 1b topline results for ALKS 7290 in adults with ADHD; results have already been pre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL2WW99h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","PSIL","MEDX","IBRN","BK4139","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669505181","title":"Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd","url":"https://stock-news.laohu8.com/highlight/detail?id=2669505181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669505181?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","PSCH","ALKS","FBT","PSIL","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150548","title":"Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150548?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","MEDX","PSCH","IBRN","PSIL","ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150512","title":"Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150512?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","PSIL","ALKS","PSCH","FBT","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","IDNA","TBXU","BMED","BK4588","LABU","PSCH","RSPH","GDOC","BK4139","MRNX","RARE","PINK","SYNB","IBB","MEDI","GNMX","LFSC","TECB","XLVX","MRNY","BK4585","IYH","IEIH","NVIB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668358979","title":"Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2668358979","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668358979?lang=en_us&edition=fundamental","pubTime":"2026-09-19 07:54","pubTimestamp":1789775650,"startTime":"0","endTime":"0","summary":"Corcept President, Oncology Roberto Wandenkolk Vieira sells 296 shares for $29,842.72Corcept’s President, Oncology Roberto Wandenkolk Vieira sold 296 common shares on Sep. 16, 2026 at $100.82.He repor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL5zJb0H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0566484027.USD","LU1559883803.SGD","CORT","BK4007","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668789973","title":"Alkermes Files Form 3 for Director Anne Clem Whitaker`","url":"https://stock-news.laohu8.com/highlight/detail?id=2668789973","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668789973?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:48","pubTimestamp":1789764537,"startTime":"0","endTime":"0","summary":"Alkermes files Form 3 for director Anne Clem Whitaker`Alkermes director Anne Clem Whitaker filed a Form 3 initial statement of beneficial ownership dated Sept. 14, 2026.Disclaimer:This news brief was ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL7wyxYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","PSIL","ALKS","MEDX","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973580","title":"Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973580","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973580?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761914,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a ster...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","MRNX","TECB","MEDI","GDOC","GNMX","LABU","LFSC","IYH","MRNY","BK4007","BK4588","NVIB","FRTY","IDNA","XLVX","BBP","PSCH","IEIH","AMRX","SYNB","RSPH","PINK","IBB","BK4585","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668273689","title":"Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668273689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668273689?lang=en_us&edition=fundamental","pubTime":"2026-09-19 00:30","pubTimestamp":1789749010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corcept Therapeutics (CORT) and Xenon (XENE) with bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-corcept-therapeutics-cort-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-corcept-therapeutics-cort-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","LU0029874061.USD","XLV","BK4585","XBI","LU0128526141.USD","LU1559883803.SGD","BK4532","SBIO","BK4007","FBT","BK4581","LABU","LU0566484027.USD","PSCH","BK4137","HCSG","CORT","BK4139","BK4588","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923679","title":"Corcept Says EU CHMP Backs Lifyorli Combo for Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923679","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:01","pubTimestamp":1789732903,"startTime":"0","endTime":"0","summary":"Corcept says EU CHMP backs Lifyorli combo for platinum-resistant ovarian cancerEU drug regulator’s CHMP backed marketing authorization for Corcept’s Lifyorli (relacorilant) with nab-paclitaxel in plat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDLcd4Vr8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","FBT","LU0566484027.USD","CORT","BK4532","PSCH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923688","title":"Corcept Therapeutics Incorporated - Ec to Issue Final Approval Decision in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923688?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:00","pubTimestamp":1789732800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUA4Q98SD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","BK4532","PSCH","CORT","BK4007","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923684","title":"Corcept Announces Chmp Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923684?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:00","pubTimestamp":1789732800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUA4Q98SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","LU0566484027.USD","LU1559883803.SGD","FBT","BK4007","CORT","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668282679","title":"Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111","url":"https://stock-news.laohu8.com/highlight/detail?id=2668282679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668282679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:35","pubTimestamp":1789731320,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI, also...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","TECB","FRTY","MRNX","RARE","IBB","MEDI","BK4139","IDNA","ABEO","NVIB","TBXU","PINK","BMED","GNMX","GDOC","SYNB","BBP","BK4588","LABU","LFSC","IYH","RSPH","BK4585","PSCH","IEIH","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994030","title":"Ultragenyx confirms FDA approval of Fayuvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994030","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994030?lang=en_us&edition=fundamental","pubTime":"2026-09-18 03:55","pubTimestamp":1789674924,"startTime":"0","endTime":"0","summary":"Ultragenyx (RARE) announced that the U.S. FDA granted standard full approval of Fayuvi, also known as UX111, for the treatment of pediatric patient...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","PINK","PSCH","BK4588","TBXU","TECB","LFSC","MRNX","LABU","BK4585","NVIB","BK4139","FRTY","IBB","RARE","BBP","IEIH","BMED","MRNY","XLVX","SYNB","RSPH","GDOC","IYH","GNMX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}